-+ 0.00%
-+ 0.00%
-+ 0.00%

Retension Pharmaceuticals Names Pavan Cheruvu to Board of Directors

PUBT·11/18/2026 13:04:13
Diffusion vocale
Retension Pharmaceuticals Names Pavan Cheruvu to Board of Directors
  • Retension Pharmaceuticals added Pavan Cheruvu to its board; he is Amanat Acquisition’s CEO and formerly led Bitterroot Bio.
  • Alison D. Schecter became chief medical officer, bringing experience overseeing three hypertension registration trials at Mineralys Therapeutics.
  • Alex Schwartz joined as chief financial officer from Ventyx Biosciences, where he led financial planning and investor relations.
  • LeAnne Bloedon became executive vice president, clinical development and operations; she previously served as head of development at Esperion Therapeutics.
  • A newly formed Scientific Advisory Board brings together five investigators in hypertension, cardiology and nephrology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Retension Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180800PRIMZONEFULLFEED9880034) on November 18, 2026, and is solely responsible for the information contained therein.